Non-parenchymal cells: key targets for modulating chronic liver diseases

Area of Science:

• Hepatology
• Immunology
• Cell Biology

Background:

• Chronic liver diseases (CLDs) present a global health burden due to progressive fibrosis.
• Non-parenchymal cells (NPCs), including liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), Kupffer cells (KCs), and innate immune lymphocytes (NK/NKT cells), are key drivers of CLD progression.
• Chronic liver injury induces detrimental changes in NPCs, leading to extracellular matrix deposition and immune dysregulation.

Purpose of the Study:

• To review recent advances in understanding NPC-driven mechanisms in chronic liver injury and fibrosis.
• To highlight the roles of LSEC dysfunction, HSC activation, and KC/NK/NKT cell-mediated inflammation.
• To explore emerging therapeutic strategies targeting NPC-specific pathways.

Main Methods:

• Literature review of recent advances in NPC research in CLDs.
• Analysis of mechanisms underlying LSEC dysfunction, HSC activation, and KC/NK/NKT cell inflammation.
• Examination of novel therapeutic approaches targeting NPC pathways.

Main Results:

• NPCs critically influence the fibro-inflammatory remodeling characteristic of CLDs.
• Dysfunctional LSECs, activated HSCs, and inflammatory KCs/NK/NKT cells exacerbate liver fibrosis.
• Targeting NPC-specific pathways shows promise for novel antifibrotic therapies.

Conclusions:

• NPCs are central to the pathogenesis of chronic liver diseases.
• Therapeutic strategies modulating NPC functions offer a promising avenue for treating liver fibrosis.
• Further research into NPC-targeted therapies is crucial for advancing CLD management.